ABVX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

ABVX ▲ +5.28% at T+20d

NEUTRAL call ✓ call won +5.28% · α vs SPY -3.62% · entry $110.17 → $115.99

Next anchor: T+60d in 7d

Currently $102.72 · -6.76% from $110.17 entry

Entry anchored
Mar 23, 03:59 PM ET
via Databento tick

T+1d

+0.48%

call +0.48% · α -0.09%

$110.70

settled 3mo ago

T+5d

+1.07%

call +1.07% · α +1.49%

$111.35

settled 2mo ago

T+20d

+5.28%

call +5.28% · α -3.62%

$115.99

settled 7w ago

T+60d

—

call — · α —

—

in 7d

Price Chart

Loading chart...

Executive Summary

Abivax reported full-year 2025 financial results with a net loss of €336.1 million, driven by higher R&D and G&A expenses, but strengthened its balance sheet with €530.4 million in cash after a $700.3 million public offering. The company remains on track to report topline Phase 3 data for obefazimod in ulcerative colitis in late Q2 2026, and appointed a new Chief Commercial Officer to prepare for potential commercialization.

Key Financial Metrics

Revenue

$4.6M

-62.9% YoY

EPS

$-1.34

Actionable Insight

Traders should monitor late Q2 2026 for topline Phase 3 data from the ABTECT-UC trial, which will be a major catalyst. The strong cash runway into Q4 2027 supports continued development, but profitability remains distant.

Key Facts

Net loss widened to €336.1 million in 2025 from €176.2 million in 2024
Cash, cash equivalents, and short-term investments totaled €530.4 million as of December 31, 2025
Raised $700.3 million (€597.2 million) in a public offering in July 2025
DSMB found no new safety signals in the Phase 3 ABTECT-UC trial; topline results expected late Q2 2026
Appointed Michael Nesrallah as Chief Commercial Officer to lead launch preparation for obefazimod

Financial Impact

Cash position increased by €372.5 million net of operations and financing; operating loss increased by €73.1 million year-over-year

cashnet_lossoperating_lossr_and_d_expenseg_and_a_expense

Risk Factors

Clinical trial results may not meet endpoints despite favorable safety data
High cash burn rate: €161.1 million used in operations in 2025
Dilution from the $700.3 million public offering may pressure shares if results disappoint

Market Snapshot

Exchange

OTC

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3260837

2 reports for ABVX

T+1T+5T+20T+60

Filters

Reports for ABVX — sortable, filterable
	Type				Now
May 22, 2026 18d ago	Press Release NEUTRAL ★ 5/10	$126.41 $129.69	▲ +2.59%	▲ +1.51%	$102.72 (−18.74%)
Mar 23, 2026 11w ago	Press Release MIXED ★ 6/10	$110.17 $111.35	▲ +1.07%	▲ +1.49%	$102.72 (−6.76%)

US Market Status

Market Closed — Opens Thu (11h 21m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access